Key facts for NCD 250.3
- Benefit category
- Drugs and Biologicals
- Effective date
- 10/01/2002
- Implemented 10/01/2002
- Transmittal
- Transmittal 155
- Versions published
- 1
TL;DR
NCD 250.3 sets Medicare's national policy for intravenous immune globulin for the treatment of autoimmune mucocutaneous blistering diseases under the benefit category "Drugs and Biologicals", effective 10/01/2002 and implemented 10/01/2002. Effective October 1, 2002, IVIg is covered for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid (a.k.a., Cicatricial Pemphigoid), and (5) Epidermolysis Bullosa Acquisita… It has been revised once since publication and binds every Medicare Administrative Contractor nationally.
Item or service described
Intravenous immune globulin (IVIg) is a blood product prepared from the pooled plasma of donors. It has been used to treat a variety of autoimmune diseases, including mucocutaneous blistering diseases. It has fewer side effects than steroids or immunosuppressive agents.
Indications and limitations of coverage
Effective October 1, 2002, IVIg is covered for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid (a.k.a., Cicatricial Pemphigoid), and (5) Epidermolysis Bullosa Acquisita for the following patient subpopulations:
• Patients who have failed conventional therapy. Medicare Administrative Contractors (MACs) have the discretion to define what constitutes failure of conventional therapy;
• Patients in whom conventional therapy is otherwise contraindicated. Contractors have the discretion to define what constitutes contraindications to conventional therapy; or
• Patients with rapidly progressive disease in whom a clinical response could not be affected quickly enough using conventional agents. In such situations IVIg therapy would be given along with conventional treatment(s) and the IVIg would be used only until the conventional therapy could take effect.
In addition, IVIg for the treatment of autoimmune mucocutaneous blistering diseases must be used only for short-term therapy and not as a maintenance therapy. Contractors have the discretion to decide what constitutes short-term therapy.
Text reproduced from the CMS Medicare Coverage Database record for NCD 250.3 version 1. View the original on cms.gov.
Local policies that build on this NCD
6 active Local Coverage Determinations cite NCD 250.3 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.
- LCD L34314: Immune Globulin Intravenous (IVIg) · Noridian Healthcare Solutions, LLC
- Intravenous Immunoglobulin (IVIG), LCD L34580 · Palmetto GBA
- Immune Globulins (L34771) · Wisconsin Physicians Service Insurance Corporation
- LCD L35093: Immune Globulin · Novitas Solutions, Inc.
- Off-Label Use of Intravenous Immune Globulin (IVIG), LCD L39314 · Wellpoint Federal
- L34007 Immune Globulin · First Coast Service Options, Inc.
How MACs bill NCD 250.3
A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 9 current articles in the Medicare Coverage Database name NCD 250.3, 8 of them with a covered ICD-10-CM list, from 5 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.
| Contractor | Articles |
|---|---|
| First Coast Service Options, Inc. | A57778 |
| Noridian Healthcare Solutions, LLC | A54641, A54643, A57187 |
| Novitas Solutions, Inc. | A56786 |
| Wellpoint Federal | A52399, A59105, A52855 |
| Wisconsin Physicians Service Insurance Corporation | A57554 |
A52399: Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars
Billing and Coding, effective 2026-10-01 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record
434 covered ICD-10-CM codes in 2 groups; 11 procedure codes: J0897, Q5136, Q5157, Q5158, Q5159, Q5162, Q5165, Q5166, Q5167, Q5171, Q5173. Local policy: L33394 Drugs and Biologicals, Coverage of, for Label and Off-Label Uses. Check a diagnosis for J0897.
First covered codes: C33 Malignant neoplasm of trachea; C34.00 Malignant neoplasm of unspecified main bronchus; C34.01 Malignant neoplasm of right main bronchus; C34.02 Malignant neoplasm of left main bronchus; C34.10 Malignant neoplasm of upper lobe, unspecified bronchus or lung; C34.11 Malignant neoplasm of upper lobe, right bronchus or lung; …
A54641: Billing and Coding: Intravenous Immune Globulin (IVIg)-NCD 250.3
Billing and Coding, effective 2015-11-07 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911) · CMS record
14 covered ICD-10-CM codes. Local policy: L34314 Immune Globulin Intravenous (IVIg).
First covered codes: L10.0 Pemphigus vulgaris; L10.1 Pemphigus vegetans; L10.2 Pemphigus foliaceous; L10.3 Brazilian pemphigus [fogo selvagem]; L10.4 Pemphigus erythematosus; L10.5 Drug-induced pemphigus; …
A54643: Billing and Coding: Intravenous Immune Globulin (IVIg)-NCD 250.3
Billing and Coding, effective 2015-11-07 · Noridian Healthcare Solutions, LLC (02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record
14 covered ICD-10-CM codes.
First covered codes: L10.0 Pemphigus vulgaris; L10.1 Pemphigus vegetans; L10.2 Pemphigus foliaceous; L10.3 Brazilian pemphigus [fogo selvagem]; L10.4 Pemphigus erythematosus; L10.5 Drug-induced pemphigus; …
A56786: Billing and Coding: Immune Globulin
Billing and Coding, effective 2026-07-01 · Novitas Solutions, Inc. (04111, 04112, 04211, 04212, 04311, 04312, 04411, 04412, 04911, 07101, 07102, 07201, 07202, 07301, 07302, 12101, 12102, 12201, 12202, 12301, 12302, 12401, 12402, 12501, 12502, 12901) · CMS record
108 covered ICD-10-CM codes in 2 groups; 18 procedure codes: J1459, J1551, J1552, J1553, J1554, J1555, J1556, J1557, J1558, J1559, J1561, J1566 and 6 more. Local policy: L35093 Immune Globulin. Check a diagnosis for J1459.
First covered codes: C90.00 Multiple myeloma not having achieved remission; C90.02 Multiple myeloma in relapse; C91.10 Chronic lymphocytic leukemia of B-cell type not having achieved remission; C91.12 Chronic lymphocytic leukemia of B-cell type in relapse; D59.0 Drug-induced autoimmune hemolytic anemia; D59.11 Warm autoimmune hemolytic anemia; …
A57187: Billing and Coding: Immune Globulin Intravenous (IVIg)
Billing and Coding, effective 2026-07-01 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record
103 covered ICD-10-CM codes; 13 procedure codes: J1459, J1552, J1553, J1554, J1556, J1557, J1561, J1566, J1568, J1569, J1576, J1577 and 1 more. Local policy: L34314 Immune Globulin Intravenous (IVIg). Check a diagnosis for J1459.
First covered codes: B20 Human immunodeficiency virus [HIV] disease; B25.0 Cytomegaloviral pneumonitis; B25.1 Cytomegaloviral hepatitis; B25.2 Cytomegaloviral pancreatitis; B25.8 Other cytomegaloviral diseases; C90.00 Multiple myeloma not having achieved remission; …
A57554: Billing and Coding: Immune Globulins
Billing and Coding, effective 2026-07-01 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record
1,176 covered ICD-10-CM codes in 14 groups; 28 procedure codes: 90371, 90375, 90376, 90393, 90396, 96365, 96366, 96372, J0840, J0850, J1459, J1460 and 16 more. Local policy: L34771 Immune Globulins. Check a diagnosis for 90371.
First covered codes: D80.0 Hereditary hypogammaglobulinemia; D80.1 Nonfamilial hypogammaglobulinemia; D80.2 Selective deficiency of immunoglobulin A [IgA]; D80.3 Selective deficiency of immunoglobulin G [IgG] subclasses; D80.4 Selective deficiency of immunoglobulin M [IgM]; D80.5 Immunodeficiency with increased immunoglobulin M [IgM]; …
A57778: Billing and Coding: Immune Globulin
Billing and Coding, effective 2026-07-01 · First Coast Service Options, Inc. (09101, 09102, 09201, 09202, 09302) · CMS record
108 covered ICD-10-CM codes in 2 groups; 18 procedure codes: J1459, J1551, J1552, J1553, J1554, J1555, J1556, J1557, J1558, J1559, J1561, J1566 and 6 more. Local policy: L34007 Immune Globulin. Check a diagnosis for J1459.
First covered codes: C90.00 Multiple myeloma not having achieved remission; C90.02 Multiple myeloma in relapse; C91.10 Chronic lymphocytic leukemia of B-cell type not having achieved remission; C91.12 Chronic lymphocytic leukemia of B-cell type in relapse; D59.0 Drug-induced autoimmune hemolytic anemia; D59.11 Warm autoimmune hemolytic anemia; …
A59105: Billing and Coding: Off-Label Use of Intravenous Immune Globulin (IVIG)
Billing and Coding, effective 2026-07-01 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record
307 covered ICD-10-CM codes in 2 groups; 13 procedure codes: 96365, 96366, J1459, J1554, J1556, J1557, J1561, J1566, J1568, J1569, J1576, J1577 and 1 more. Local policy: L39314 Off-Label Use of Intravenous Immune Globulin (IVIG). Check a diagnosis for 96365.
First covered codes: D60.0 Chronic acquired pure red cell aplasia; D60.1 Transient acquired pure red cell aplasia; D60.8 Other acquired pure red cell aplasias; D60.9 Acquired pure red cell aplasia, unspecified; D89.810 Acute graft-versus-host disease; D89.811 Chronic graft-versus-host disease; …
A52855: Billing and Coding: Drugs and Biologicals
Billing and Coding, effective 2026-04-01 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record
No covered diagnosis list. Local policy: L33394 Drugs and Biologicals, Coverage of, for Label and Off-Label Uses.
Coverage analysis history
CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links one analysis to NCD 250.3, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.
- CAG-00109N Intravenous Immune Globulin for Autoimmune Mucocutaneous Blistering Diseases (New, Closed)
Revision history
03/2025 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations (NCDs). No policy is being changed as a result of these updates. ( TN 13097 ) (CR13939)
01/2024 - Transmittal 12350 issued November 03, 2023, is being rescinded and replaced by Transmittal 12440 dated January 3, 2024, to make changes to NCD 90.2, Next Generation Sequencing, spreadsheet to align with revisions being made to CR 13278. All other information remains the same. ( TN 12440 ) (CR13391)
11/2023 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations (NCDs). No policy is being changed as a result of these updates.( TN 12350 ) (CR13391)
10/2023 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations (NCDs). No policy is being changed as a result of these updates. ( TN 12319 ) (CR13391)
12/2015 - This change request (CR) is the 3rd maintenance update of ICD-10 conversions/updates specific to national coverage determinations (NCDs). The majority of the NCDs included are a result of feedback received from previous ICD-10 NCD CR7818, CR8109, CR8197, CR8691, & CR9087. Some are the result of revisions required to other NCD-related CRs released separately that included ICD-10 coding. Implementation date: 01/04/2016 Effective date: 10/1/2015. ( TN 1580 ) (CR9252)
08/2015 - This change request (CR) is the 3rd maintenance update of ICD-10 conversions/updates specific to national coverage determinations (NCDs). The majority of the NCDs included are a result of feedback received from previous ICD-10 NCD CR7818, CR8109, CR8197, CR8691, & CR9087. Some are the result of revisions required to other NCD-related CRs released separately that included ICD-10 coding.
These updates do not expand, restrict, or alter existing coverage policy. Implementation date: 01/04/2016 Effective date: 10/1/2015. ( TN 1537 ) (CR 9252)
05/2014 - CMS translated the information for this policy from ICD-9-CM/PCS to ICD-10-CM/PCS according to HIPAA standard medical data code set requirements and updated any necessary and related coding infrastructure. These updates do not expand, restrict, or alter existing coverage policy. Implementation date: 10/06/2014 Effective date: 10/1/2015. ( TN 1388 ) ( TN 1388 ) (CR 8691)
09/2012 - CMS translated the information for this policy from ICD-9-CM/PCS to ICD-10-CM/PCS according to HIPAA standard medical data code set requirements and updated any necessary and related coding infrastructure. These updates do not expand, restrict, or alter existing coverage policy.Implementation date: 01/07/2013 Effective date: 10/1/2015. ( TN 1122 ) ( TN 1122 ) (CR 7818)
05/2002 - Provided limited coverage for use of IVIg for treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid (a.k.a., Cicatricial Pemphigoid), and (5) Epidermolysis Bullosa Acquisita. Effective and implementation dates 10/01/2002. ( TN 155 ) (CR 2149)
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
For teams evaluating QuickIntell software
Evaluate a coverage-review workflow around NCD 250.3
Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — NCD 250.3
What does NCD 250.3 cover?
Effective October 1, 2002, IVIg is covered for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid (a.k.a., Cicatricial Pemphigoid), and (5) Epidermolysis Bullosa Acquisita for the following patient subpopulations: The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 250.3 take effect?
The current version (1) is effective 10/01/2002, implemented 10/01/2002, published in transmittal 155. This is the only published version.
Does a Local Coverage Determination override NCD 250.3?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- Medicare Coverage Database national coverage analyses (NCA/CAL report) via the CMS Coverage APIVersion API snapshot 2026-11-16 · effective 2026-11-16 · file national-coverage-ncacal.jsonSHA-256 563369a07b95140a…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.